A Phase 2 interventional study of AL001 in Frontotemporal Dementia, sponsored by Alector Inc.. Completed at 12 sites in 6 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-12-05.
Sponsored by Alector Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies in Frontotemporal Dementia with a site in United States — 31 open to participants now, 45 under way, none of them phase 3. Frontotemporal Dementia · United States.
Among the 103 studies in Frontotemporal Dementia with a site in United States, this one is the 44th largest by enrollment of the 66 interventional ones that give a count, is one of 7 that started in 2019, is one of 14 in phase 2, and was the 52nd registered.
208 studies on the registry are indexed under Frontotemporal Dementia; 72 are open to participants now.
Browse Frontotemporal Dementia studies →31 of the 103 studies in Frontotemporal Dementia with a site in United States are open now. Recruiting first, the newest first:
Institute for Molecular Medicine · Sites in United States
Ages 65–80
Maya Henry · Sites in United States
Ages 40+
Oregon Health and Science University · Sites in United States
Ages 18–100 · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 45+ · Healthy volunteers
University of Chicago · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 51 Frontotemporal Dementia studies recruiting now, 29 (57%) set no upper age limit and 5 (10%) stop at 75 or younger; 6 take children under 18; 30 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 19 · Phase 3 5 · Phase 4 3
First in 2001; this study’s year is marked. 7 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 50 across 128 interventional studies indexed under Frontotemporal Dementia.
Median enrollment 60 across the 66 interventional studies, 201 across the 37 observational. Of the 52 that completed or were terminated, 17 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 103 have an industry lead sponsor. The 10 most frequent:
Alector Inc. is the lead sponsor of 10 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 5 (50%) have results posted.
Alector Inc. has 4 studies filed under Frontotemporal Dementia — fewer than ten, so there is no comparison to draw.
14 of the studies in Frontotemporal Dementia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05262023Denali Therapeutics Inc.A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN) | 2026-12 |
| NCT03233646Duke UniversityRetinal Imaging in Neurodegenerative Disease | 2026-12-31 |
| NCT03702907Georgetown UniversityDC Longitudinal Study on Aging and Specimen Bank | 2027-01 |
| NCT05184569Peter Ljubenkov, MDVeri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology | 2027-01-31 |
| NCT04516499The Bluefield Project to Cure Frontotemporal DementiaNeurofilament Surveillance Project (NSP) | 2027-02 |
Add all 14 to your calendar (.ics) → With an account.
Among the 103 studies in Frontotemporal Dementia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase 2 open label study evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AL001 in participants with a Granulin mutation or C9orf72 mutation causative of frontotemporal dementia.
This is a Phase 2, multicenter, open label study evaluating the safety, tolerability, PK and PD of AL001 administered intravenously in participants with a Granulin mutation or C9orf72 mutation causative of frontotemporal dementia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IV administration of AL001; 60 mg/kg, every 4 weeks \[q4w\]
Drug: AL001
60 mg/kg of AL001 every 4 weeks
Severity of TEAEs
Number of TEAEs categorized by severity
Time frame: 197 weeks
Severity of Treatment-Related TEAEs
Number of treatment-related TEAEs categorized by severity
Time frame: 197 weeks
Any TEAE Leading to Study Drug Discontinuation
Number of TEAEs leading to study drug discontinuation
Time frame: 197 weeks
Immunogenicity Antidrug Antibodies (ADA) Titer
Titer values of antidrug antibodies (ADAs) in participants receiving latozinemab at week 97/Part 1 end of study
Time frame: 97 weeks
Confirmatory Immunogenicity Antidrug Antibodies (ADA) Responses
Presence of confirmatory antidrug antibodies (ADAs) in participants who test positive for ADA at week 97 (Part 1 End of Study).
Time frame: 97 weeks
Change From Baseline in Sheehan Suicidality Tracking Scale
The Sheehan Suicidality Tracking Scale (S-STS) is a structured assessment tool used to evaluate the presence, severity, and frequency of suicidal ideation and behavior. It includes items that address passive thoughts of death, active suicidal ideation, intent, planning, suicide attempts, and non-suicidal self-injury. The S-STS total score ranges from 0 to 64, based on 16 items each rated from 0 (not at all) to 4 (extremely), with higher scores indicating greater severity of suicidal ideation, intent, or behavior. The total score provides a quantitative measure of suicidality severity and is sensitive to change over time, making it suitable for clinical monitoring and research use.
Time frame: 197 weeks
Longitudinal Percent Change From Baseline of CSF PGRN
The percent change from baseline to specified timepoints of PGRN in CSF. The baseline visit is labeled as week 1 and therefore the 96th week is labeled as week 97.
Time frame: 97 weeks
Longitudinal Percent Change From Baseline in Plasma PGRN
The percent change from baseline to specified timepoints for PGRN in plasma. The baseline visit is labeled as week 1 and therefore the 96th week is labeled as week 97.
Time frame: 97 weeks
Longitudinal Levels of Sortilin in WBCs
The overall change from baseline in Sortilin in WBCs.
Time frame: 97 weeks
Latozinemab Concentration in Serum
Serum concentration of Latozinemab at week 97.
Time frame: 97 weeks
Cmax of Latozinemab at Specified Timepoints
Maximum observed concentration of Latozinemab at week 96 of treatment.
Time frame: 97 weeks
Ctrough of Latozinemab at Specified Timepoints
Trough concentration of Latozinemab at week 96 of treatment
Time frame: 97 weeks
ARCmax of Latozinemab
Ratio of latozinemab Cmax at week 61 to the Cmax at week 1
Time frame: 61 weeks
| Milestone | aFTD-GRN | FTD-GRN | FTD-C9orf72 |
|---|---|---|---|
| Started | 5 | 12 | 16 |
| Completed | 5 | 5 | 6 |
| Not completed | 0 | 7 | 10 |
Number of TEAEs categorized by severity
| TEAEs (all) | aFTD-GRN | FTD-GRN | FTD-C9orf72 |
|---|---|---|---|
| Mild | 43 | 58 | 84 |
| Moderate | 4 | 9 | 24 |
| Severe | 3 | 1 | 4 |
| Life Threatening | 0 | 0 | 0 |
| Death | 0 | 0 | 1 |
Number of treatment-related TEAEs categorized by severity
| TEAEs (treatment-related) | aFTD-GRN | FTD-GRN | FTD-C9orf72 |
|---|---|---|---|
| Mild | 5 | 1 | 12 |
| Moderate | 1 | 1 | 5 |
| Severe | 0 | 0 | 0 |
| Life Threatening | 0 | 0 | 0 |
| Death | 0 | 0 | 0 |
Number of TEAEs leading to study drug discontinuation
| TEAE leading to discontinuation | aFTD-GRN | FTD-GRN | FTD-C9orf72 |
|---|---|---|---|
| Any TEAE Leading to Study Drug Discontinuation | 0 | 1 | 1 |
Titer values of antidrug antibodies (ADAs) in participants receiving latozinemab at week 97/Part 1 end of study
| Titers | aFTD-GRN | FTD-GRN | FTD-C9orf72 |
|---|---|---|---|
| Week 2 - ADA Titer | 320.0 (20 to 5120) | 20.0 (20 to 2560) | 40.0 ± 0.00 |
| Week 13 - ADA Titer | 160.0 (20 to 2560) | 160.0 (160 to 640) | 120.0 (80 to 160) |
| Week 25 - ADA Titer | 320.0 (320 to 320) | 330.0 (20 to 640) | 80.0 (20 to 160) |
| Week 37 - ADA Titer | 0 (0 to 0) | 80.0 (20 to 320) | 90.0 (20 to 160) |
| Week 49 - ADA Titer | 0 (0 to 0) | 320.0 (40 to 640) | 20.0 (20 to 20) |
| Week 61 - ADA Titer | 0 (0 to 0) | 0 (0 to 0) | 160.0 (160 to 160) |
| Week 73 - ADA Titer | 0 (0 to 0) | 160.0 (160 to 160) | 0 (0 to 0) |
| Week 85 - ADA Titer | 0 (0 to 0) | 160.0 (160 to 160) | 20.0 (20 to 20) |
| Week 97 - ADA Titer | 20.0 (20 to 20) | 0 (0 to 0) | 160.0 (160 to 160) |
Presence of confirmatory antidrug antibodies (ADAs) in participants who test positive for ADA at week 97 (Part 1 End of Study).
| Participants | aFTD-GRN | FTD-GRN | FTD-C9orf72 |
|---|---|---|---|
| ADA Positive | 1 | 0 | 2 |
| ADA Negative | 4 | 5 | 7 |
The Sheehan Suicidality Tracking Scale (S-STS) is a structured assessment tool used to evaluate the presence, severity, and frequency of suicidal ideation and behavior. It includes items that address passive thoughts of death, active suicidal ideation, intent, planning, suicide attempts, and non-suicidal self-injury. The S-STS total score ranges from 0 to 64, based on 16 items each rated from 0 (not at all) to 4 (extremely), with higher scores indicating greater severity of suicidal ideation, intent, or behavior. The total score provides a quantitative measure of suicidality severity and is sensitive to change over time, making it suitable for clinical monitoring and research use.
| Scores | aFTD-GRN | FTD-GRN | FTD-C9orf72 |
|---|---|---|---|
| Change From Baseline in Sheehan Suicidality Tracking Scale | 0 ± 0 | 0 | 0 ± 0 |
The percent change from baseline to specified timepoints of PGRN in CSF. The baseline visit is labeled as week 1 and therefore the 96th week is labeled as week 97.
| percent change of ug/L | aFTD-GRN | FTD-GRN | FTD-C9orf72 |
|---|---|---|---|
| Week 49 | 198.16 ± 110.255 | 104.05 ± 103.349 | 101.61 ± 38.492 |
| Week 97 | 189.46 ± 113.802 | 59.73 ± 24.034 | 144.73 ± 54.994 |
The percent change from baseline to specified timepoints for PGRN in plasma. The baseline visit is labeled as week 1 and therefore the 96th week is labeled as week 97.
| percent change in ug/L | aFTD-GRN | FTD-GRN | FTD-C9orf72 |
|---|---|---|---|
| Week 49 | 177.39 ± 51.352 | 151.32 ± 59.321 | 178.82 ± 58.406 |
| Week 97 | 185.37 ± 43.763 | 188.12 ± 47.847 | 157.93 ± 92.695 |
The overall change from baseline in Sortilin in WBCs.
No measurements were reported for this outcome.
Serum concentration of Latozinemab at week 97.
| ng/mL | aFTD-GRN | FTD-GRN | FTD-C9orf72 |
|---|---|---|---|
| Latozinemab Concentration in Serum | 236000 ± 69100 | 250000 ± 24700 | 265000 ± 77000 |
Maximum observed concentration of Latozinemab at week 96 of treatment.
| ug/mL | aFTD-GRN | FTD-GRN | FTD-C9orf72 |
|---|---|---|---|
| Cmax of Latozinemab at Specified Timepoints | 1810 ± 352 | 1320 ± 255 | 1510 ± 145 |
Trough concentration of Latozinemab at week 96 of treatment
| ug/mL | aFTD-GRN | FTD-GRN | FTD-C9orf72 |
|---|---|---|---|
| Ctrough of Latozinemab at Specified Timepoints | 236 ± 69.1 | 250 ± 24.7 | 252 ± 66.7 |
Ratio of latozinemab Cmax at week 61 to the Cmax at week 1
| Ratio | aFTD-GRN | FTD-GRN | FTD-C9orf72 |
|---|---|---|---|
| ARCmax of Latozinemab | 1.22 ± 0.192 | 1.23 ± 0.236 | 1.39 ± 0.712 |
Collected over 197 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| aFTD-GRN | 0/5 (0%) | 1/5 (20%) | 4/5 (80%) |
| FTD-GRN | 0/12 (0%) | 3/12 (25%) | 9/12 (75%) |
| FTD-C9orf72 | 1/16 (6.3%) | 2/16 (12.5%) | 13/16 (81.3%) |
| Event | aFTD-GRN | FTD-GRN | FTD-C9orf72 |
|---|---|---|---|
| Lip and/or oral cavity cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/5 | 0/12 | 0/16 |
| Amyotrophic lateral sclerosisNervous system disorders | 0/5 | 0/12 | 2/16 |
| Procedural pneumothoraxInjury, poisoning and procedural complications | 0/5 | 1/12 | 0/16 |
| Deep vein thrombosisVascular disorders | 0/5 | 1/12 | 0/16 |
| SyncopeNervous system disorders | 0/5 | 1/12 | 0/16 |
| AggressionPsychiatric disorders | 0/5 | 0/12 | 1/16 |
| Event | aFTD-GRN | FTD-GRN | FTD-C9orf72 |
|---|---|---|---|
| FallInjury, poisoning and procedural complications | 2/5 | 5/12 | 7/16 |
| DizzinessNervous system disorders | 2/5 | 0/12 | 0/16 |
| Back painMusculoskeletal and connective tissue disorders | 2/5 | 0/12 | 0/16 |
| COVID-19Infections and infestations | 2/5 | 0/12 | 5/16 |
| Upper respiratory tract infectionInfections and infestations | 2/5 | 0/12 | 1/16 |
| Urinary tract infectionInfections and infestations | 1/5 | 2/12 | 6/16 |
| Subclavian artery occlusionVascular disorders | 1/5 | 0/12 | 0/16 |
| Infusion site extravasationGeneral disorders | 1/5 | 0/12 | 0/16 |
| Infusion site painGeneral disorders | 1/5 | 0/12 | 0/16 |
| Infusion site paraesthesiaGeneral disorders | 1/5 | 0/12 | 0/16 |
| Age, Categorical(Participants) | aFTD-GRN | FTD-GRN | FTD-C9orf72 | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 5 | 7 | 11 | 23 |
| >=65 years | 0 | 5 | 5 | 10 |
| Age, Continuous(years) | aFTD-GRN | FTD-GRN | FTD-C9orf72 | Total |
|---|---|---|---|---|
| Median | 59.0 (32 to 63) | 59.5 (48 to 78) | 60.0 (40 to 74) | 59.0 (32 to 78) |
| Sex: Female, Male(Participants) | aFTD-GRN | FTD-GRN | FTD-C9orf72 | Total |
|---|---|---|---|---|
| Female | 1 | 4 | 9 | 14 |
| Male | 4 | 8 | 7 | 19 |
| Ethnicity (NIH/OMB)(Participants) | aFTD-GRN | FTD-GRN | FTD-C9orf72 | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 0 | 2 |
| Not Hispanic or Latino | 5 | 10 | 16 | 31 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | aFTD-GRN | FTD-GRN | FTD-C9orf72 | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 5 | 10 | 16 | 31 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 2 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2019 to primary completion in Jun 2024, 56 months.
Results were first posted in Aug 2025, 1 year 2 months after primary completion.
Of 19 phase 2 interventional studies under Frontotemporal Dementia, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 64. This study's 56 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Latozinemab
Alector Inc.